ATA

Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy, focusing on developing "off-the-shelf" treatments for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company leverages its novel Epstein-Barr Virus (EBV) T-cell platform to create therapies that harness the power of the immune system without the need for patient-specific customization. Their lead product, Ebvallo (tabelecleucel), is the first-ever allogeneic T-cell therapy to receive regulatory approval (in the EU) for EBV-positive post-transplant lymphoproliferative disorder. Atara continues to advance a robust pipeline of CAR-T and TCR therapies targeting various antigens like CD19 and mesothelin, while also investigating the role of EBV-targeted T-cells in treating progressive multiple sclerosis.